Compugen (CGEN)

• Market cap: $154M
• 1 day: 2.48%
• 5 days: 1.23%
• 1 month: -25.68%
• 3 months: 3.77%
• 6 months: -14.06%
• Year to date: 0.00%
• 1 year: -38.43%
• 5 years: -77.18%
• 10 years: -78.35%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Employees: 74

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

178% more call options, than puts

Call options by funds: $111K | Put options by funds: $40K

75% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 8

8% more funds holding

Funds holding: 65 [Q3] → 70 (+5) [Q4]

0.18% more ownership

Funds ownership: 13.46% [Q3] → 13.65% (+0.18%) [Q4]

7% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 15

14% less capital invested

Capital invested by funds: $21.8M [Q3] → $18.7M (-$3.11M) [Q4]